GLP-1 and Cholesterol: How Ozempic and Wegovy Improve Your Lipid Panel

GLP-1 and Cholesterol: How Ozempic and Wegovy Improve Your Lipid Panel

By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist and founder of Casa de Sante

Understanding Your Lipid Panel

What the Numbers Mean

• Total cholesterol: Less useful than individual components. Target <200 mg/dL.
• LDL ("bad" cholesterol): The primary driver of atherosclerosis. Target depends on risk: <100 for most adults, <70 for high-risk patients.
• HDL ("good" cholesterol): Removes cholesterol from arteries. Higher is better. Target >40 (men), >50 (women).
• Triglycerides: Fat in the blood. Strongly influenced by diet, alcohol, and insulin resistance. Target <150 mg/dL.
• ApoB: Emerging marker. Better predictor of cardiovascular risk than LDL alone. Measures the actual number of atherogenic particles.

How GLP-1 Improves Cholesterol

Direct Mechanisms (Independent of Weight Loss):

• Reduced hepatic VLDL production: GLP-1 receptors in the liver reduce the production of VLDL (the precursor to LDL). Less VLDL = less LDL.
• Reduced intestinal lipid absorption: GLP-1 slows gastric emptying, which reduces the rate of lipid absorption from meals. Slower absorption = lower postprandial triglycerides.
• Improved insulin sensitivity: Insulin resistance drives dyslipidemia (high triglycerides, low HDL, small dense LDL). GLP-1 medications improve insulin sensitivity, which corrects the underlying metabolic driver.
• Reduced inflammation: CRP (C-reactive protein) decreases significantly on GLP-1. Inflammation drives atherosclerosis independent of cholesterol levels.

Weight Loss Effects:

• Every 1% body weight loss reduces LDL by ~1 mg/dL
• Visceral fat loss (the type GLP-1 preferentially reduces) has the strongest impact on triglycerides
• Improved liver fat (GLP-1 reduces hepatic steatosis by 50-70%) directly reduces VLDL production

The SELECT Trial

The landmark cardiovascular outcome trial for semaglutide 2.4mg (Wegovy) in overweight/obese patients WITHOUT diabetes:

• 17,604 patients, followed for ~3 years
• 20% reduction in MACE (heart attack, stroke, cardiovascular death)
• This established GLP-1 as a cardiovascular protection medication, not just a weight loss drug
• Benefits were seen as early as 6 months — before maximum weight loss was achieved — suggesting direct cardioprotective mechanisms

Maximizing Cardiovascular Benefit

1. Mediterranean-style eating: Olive oil, fish, nuts, vegetables. Synergistic with GLP-1 for lipid improvement.
2. Omega-3 fatty acids: 2-4g EPA daily. The REDUCE-IT trial showed EPA reduced cardiovascular events by 25% on top of statin therapy.
3. Exercise: Increases HDL, reduces triglycerides. Combined with GLP-1, the effect on lipid panel is amplified.
4. Fiber: Soluble fiber (psyllium, oats) reduces LDL by 5-10% by binding bile acids.
5. Limit refined carbohydrates: Refined carbs and sugar drive triglyceride production more than dietary fat does.